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In an earlier study, we have demonstrated a high clinical and pathologic response rate of neoadjuvant paclitaxel (P) and cisplatin (C)
for patients with locally advanced breast cancer (LABC). The current phase II study includes larger number of patients who had
longer follow-up. A total of 126 consecutive patients with noninflammatory LABC (T2 44cm, T3 or T4, N0–N3, M0) were
included in the study. Patients were scheduled to receive three to four cycles of the neoadjuvant PC (paclitaxel 135mgm
 2 and
cisplatin 75mgm
 2 on day 1) every 21 days. Patients were then subjected to surgery and subsequently received six cycles of FAC (5-
fluorouracil 500mgm
 2, doxorubicin 50mgm
 2, and cyclophosphamide 500mgm
 2) or four cycles of AC (doxorubicin 60mgm
 2
and cyclophosphamide 600mgm
 2); all drugs were administered intravenously on day 1 with cycles repeated every 21 days. Patients
then received radiation therapy, and those with hormone receptor-positive tumours were given adjuvant tamoxifen intended for 5
years. The median age was 41 years. Clinically, 12, 52, and 37% of patients had T2 44cm, T3, and T4, respectively. The mean tumour
size was 7cm (95% CI, 7.3–8.5). The clinical nodal status was N0, N1, and N2–N3 in 32, 52, and 17% of patients, respectively.
Disease stage at diagnosis was IIA (2%), IIB (32%), IIIA (28%), and IIIB (39%). Clinical assessment of the primary tumour and the
axillary nodal status after primary chemotherapy showed that 35 patients (28%) achieved complete response (cCR), while 80 (63%)
demonstrated partial response to PC. Of patients with evaluable pathologic data of the primary tumour (123 patients), complete
pathologic response (pCR) was achieved in 29 patients (24%), and an additional nine (7%) only had a microinvasive disease.
Moreover, 20 of the 122 patients (16%) had no residual disease in the primary tumour or in the axillary nodes. Failure to attain cCR
predicted failure to achieve pCR. At a median follow-up of 37.5 months (95% CI, 31.5–43.3), 71% were alive with no recurrence,
16% were alive with evidence of disease, and 13% were dead. Of the 122 patients who had surgery, 36 (29%) developed recurrence
including one of the patients who attained pCR. The median overall or disease-free survival has not been reached with a projected 5-
year overall survival (OS) and disease-free survival (DFS) of 85% (74%) and 63% (75%), respectively. On multivariate analysis,
clinical response of the primary tumour, pathological response of the primary tumour, and the pathological nodal status were
identified as independent prognostic variables for DFS. No variable, however, was identified to prognosticate OS. PC was acceptably
safe. Neoadjuvant PC as used in this phase II study in a multidisciplinary strategy was highly effective. Clinical and pathologic responses
remain the most important variables that predict outcome.
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Neoadjuvant chemotherapy has been used as the initial treatment
in locally advanced breast cancer (LABC). The Milan Group, using
a combination of doxorubicin and vincristine, achieved an 80%
response rate, with 15% of patients attaining complete clinical
response (De Lena et al, 1981). Other groups have achieved
comparable results (Hortobagyi et al, 1988; Kuerer et al, 1999).
With this approach, 5-year survival rates of approximately 40%
have been reported (Valagussa et al, 1990), while significantly
higher survival rates have been reported by others (Hortobagyi
et al, 1988; Smith and al-Moundhri, 1998; Kuerer et al, 1999).
Likewise, primary chemotherapy has been used successfully for
large operable breast cancer in nonrandomised and randomised
trials (Anderson et al, 1991; Smith et al, 1993; Scholl et al, 1994;
Powles et al, 1995; Smith et al, 1995; Bonadonna et al, 1998; Fisher
et al, 1998; Von Minckwitz et al, 1999). Moreover, the National
Surgical Adjuvant Breast and Bowel Project (NSABB) B-18, one of
the largest reported studies including 1523 patients, has clearly
shown that at 9 years of follow-up, the outcome of patients who
received primary chemotherapy was equal to that for patients
treated with adjuvant chemotherapy (Wolmark et al, 2001).
However, a marginally statistically significant survival advantage
from neoadjuvant chemotherapy was noted for younger patients,
whereas the reverse may be true for older patients.
We have demonstrated the significant efficacy of the combina-
tion of paclitaxel and cisplatin (PC) in the management of patients
with metastatic breast cancer disease where an objective response
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lof 80% was achieved (Ezzat et al, 1997). The results of this phase II
study were in concordance with the reported efficacy of paclitaxel
and cisplatin used in various settings in the management of breast
cancer (Hortobagyi, 1997; Comella et al, 1998; Henderson et al,
1998; Kourousis et al, 1998; Perez et al, 1998; Volm et al, 1998).
Furthermore, both drugs have demonstrated potency on anthracy-
cline-resistant tumours (Lau et al, 1998, Ray-Coquard et al, 1998).
The lack of apparent crossresistance between paclitaxel and
cisplatin, the minimal overlapping toxicity, and the potential
angiogenesis antagonistic effect of paclitaxel that appears to be
independent of its antiproliferative action, make this combination
very appealing for the management of LABC.
In an earlier phase II report that included 72 patients with
LABC, we have demonstrated that the PC regimen was very
effective and reasonably tolerant (Ezzat et al, 2000). Complete and
partial clinical response to PC was demonstrated in 18 and 72%
patients, respectively, for an overall response of 90% (95%
confidence interval (CI), 79–100%). Moreover, complete patholo-
gic response (pCR) and partial pathologic response (pPR) was
achieved in 15 (22%) and 51 (75%) of patients, respectively, for an
overall response of 97% (95% CI, 95–99%).
The current series update the outcome of 126 patients at a
median follow-up of approximately 4 years. The primary end point
was to assess the effect of that regimen on clinical and pathological
response, while the secondary end point was to analyse the effect
on survival, and to identify predictors of response and prognostic
factors of survival.
PATIENTS AND METHODS
Between May 1995 and December 2000, consecutive patients seen
at our institution with locally advanced noninflammatory breast
cancer (T244cm, T3 or T4, N0–N2, M0) confirmed on fine needle
aspirate (FNA) and/or tru-cut biopsy were considered eligible.
Those with bilateral breast cancer, or documented evidence of
metastatic disease, including supraclavicular lymph node involve-
ment, were excluded. Also excluded were patients with a history of
renal, hepatic or heart failure, history of malignancy except basal
cell carcinoma of the skin or cervical carcinoma in situ, or history
of psychiatric disorder that might interfere with the administration
of protocol drugs or follow-up. The study intended to exclude
patients who developed breast cancer during pregnancy or those
who became pregnant during therapy; however, those events were
not encountered. Patients who experienced any grade 4 toxicity,
grade 3 or 4 neurotoxicity, those who requested withdrawal from
the study, and those who demonstrated tumour progression after
at least two cycles of the neoadjuvant regimen were removed from
the study, but were included in the analysis.
Staging procedures included complete history and physical
examination, laboratory studies, bilateral mammography, chest
and abdominal computerised tomography, and radionuclide bone
scan. Hormone receptor assay was available for most patients.
Clinical sizes of primary breast cancers and axillary nodes, if the
latter were palpable, were determined separately before the
administration of each cycle of PC and also before surgery. At
each assessment, the product of the two greatest perpendicular
diameters of the tumours in the breast and axilla was measured.
The study was approved by King Faisal Specialist Hospital and
Research Center’s Research Advisory and Ethics Committees,
Riyadh. All patients gave a written informed consent.
Therapy
Patients received three to four cycles of the neoadjuvant PC
therapy. Paclitaxel 135mgm
 2 on day 1 at 0600 hours as 3-h
infusion with the standard premedication (dexamethasone, anti-
histamine, and H2 antagonist) was initiated the night before
therapy. Cisplatin was administered as 75mgm
 2 on day 1 at 1800
hours as a 1-h infusion with standard pre- and posthydration. The
timing of drug administration was chosen in conformity with the
circadian rhythm concept in the first 42 patients (Harmanek and
Sobin, 1987). Cycles were repeated at 3-week intervals.
Following the neoadjuvant regimen, response was assessed
clinically and mammographically. Within 4 weeks after the last
cycle, patients were scheduled to undergo conservative surgery or
modified radical mastectomy upon the discretion of the surgeon
guided by the clinical response. Axillary lymph node dissection to
levels I and II was carried out aiming for excision of at least 10
lymph nodes.
Within 2–3 weeks following surgery, patients received six cycles
of FAC (5-fluorouracil 500mgm
 2, doxorubicin 50mgm
 2, and
cyclophosphamide 500mgm
 2) or four cycles of AC (doxorubicin
60mgm
 2 and cyclophosphamide 600mgm
 2); all drugs were
administered intravenously on day 1 with cycles repeated at 3-
week intervals. The choice between FAC 6  vs AC 4  was made
based on the primary oncologist’s discretion. In recent years, some
patients who demonstrated pCR were given two additional cycles
of PC. Any grade 1 toxicity was treated symptomatically and
therapy was allowed to continue. However, grade 3 myelotoxicity
required a delay in chemotherapy until bone marrow recovery,
with granulocyte colony-stimulating factor (G-CSF) support on
subsequent cycles.
Following adjuvant chemotherapy, patients received radiation
therapy to the chest wall and axilla or to the breast and the axilla,
but the supraclavicular fossa and internal mammary chains were
not routinely irradiated. Adjuvant tamoxifen 20mg orally daily
intended for 5 years was given to patients shown to have oestrogen
receptor (ER)- and/or progesterone receptor (PR)-positive tu-
mour.
Data capture
A computerised database was created to capture prospectively the
following information: patients’ demographic and clinical data,
laboratory and radiologic studies, disease characteristics, and
neoadjuvant therapy details including clinical response and
toxicity. The database also included surgery details, axillary lymph
node dissection, and pathologic data including response. Also
captured were postsurgery further chemotherapy, hormonal
therapy, radiation therapy, recurrence, and survival status.
Definitions
Staging was defined according to the criteria determined by the
International Union Against Cancer (UICC) (Harmanek and Sobin,
1987) with group clinical and pathological staging according to the
American Joint Committee on Cancer (AJCC). We adopted the
criteria for LABC reported by Haagensen and Stout (1943).
After preoperative chemotherapy was administered, breast
tumours were classified according to clinical response. In the
absence of clinical evidence of tumour in the breast without any
new lesions occurring, the response to therapy was categorised as a
clinically complete response (cCR). When the reduction in the sum
of the products of the largest perpendicular diameters of the breast
tumour was 50% or greater without the development of newer
lesions prior to surgery, the response was judged to be partial
(cPR). Clinical progressive disease (cPD) was defined as any
increase greater than 25% of the sum of the products of the largest
perpendicular diameters of any measurable lesions, or unequivocal
appearance of new lesions after a minimum of two cycles of PC.
Patients whose breast tumour response did not meet the definition
of cCR, cPR, or cPD were considered to have stable disease (cSD).
Thus, patients with cSD could have a tumour response of less than
50% or an increase in tumour size of o25%. This classification
was also used to record the response of an axillary tumour to the
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at diagnosis. The overall clinical response of both breast and
axillary tumours was determined by combining the sum of the
product of the tumour measurements in both the breast and axilla.
The development of a clinically suspicious ipsilateral axillary
tumour during chemotherapy was considered as evidence of cPD
in patients whose axilla was clinically negative at diagnosis.
A median of 15 sections of the mastectomy or lumpectomy
specimen was performed; these included sections from each
quadrant, from the nipple–areola complex (if appropriate), from
areas of suspicious or prior tumour involvement, and from the
axillary contents (a median of seven sections). Pathologic response
to neoadjuvant chemotherapy was assessed according to the
criteria modified from that used by Feldman et al (1986). Complete
pathological response of the primary (pCR) was defined as the
absence of any macroscopic or microscopic evidence of invasive
tumour in the surgical specimen. The same definition was applied
to the axillary nodes. Partial pathological response was defined as
50% or greater reduction in the sum of products of the largest
perpendicular diameters of residual lesions as compared with the
size of the primary tumour regardless of the nodal status;
pathologic stable disease (pSD) was defined as less than 50%
reduction in the sum of products of largest perpendicular
diameters of the residual disease as compared with the primary
tumour size regardless of the nodal status; and pathological
progressive disease (pPD) was defined as any increase greater than
25% of the sum of the products of largest perpendicular diameters
of residual lesions as compared with the size of primary tumour
regardless of the nodal status.
Overall survival (OS) was estimated from date of diagnosis to
date of last follow-up or death from any cause. Disease-free
survival (DFS) was calculated from the date of definitive surgery
until last contact; recurrence ‘local, regional, or distant’; occur-
rence of contralateral breast cancer; occurrence of second primary
cancer other than in the contralateral breast; or death without
evidence of breast or second primary cancer.
Statistical methods
A two-sided Wilcoxon–Pratt test was used to compare tumour
sizes before and after PC. Comparison of means and medians of
continuous variables was performed using t-test statistics and
nonparametric methods, respectively. Patient- and disease-related
variables were first examined for their relation to response, while
variables with a P-value of o0.10 were included in a stepwise
multivariate logistic regression analysis to identify the indepen-
dent predictors for pCR response (Cox and Snell, 1989). Age was
entered both as continuous and as dichotomous values by using
different cutoffs. The goodness-of-fit w
2, the Hosmer goodness-of-
fit, and the Brown goodness-of-fit tests were used to test the
hypotheses that the model at each step fits the data, that the
predicted values fit the data, and that the logistic model is the best
fitting model, respectively (Prentice, 1976; Hosmer and Lemeshow,
1980). Kappa’s test of reliability was used to compare the
agreement between clinical and pathologic response (Fleiss,
1981). Survival was estimated applying the method of Kaplan
and Meier (1958), while the statistical procedure of Brookmeyer–
Crowley was used to estimate the 95% confidence interval (CI) of
median survival (Brookmeyer and Crowley, 1982). The log-rank
test was used to assess the significance of unadjusted differences in
survival (Mantel, 1966).
Exploring variables for their independent prognostic effect on
survival was carried out using the multivariate stepwise Cox’s
proportional regression hazard model (Cox and Oakes, 1997). The
relative importance of prognostic factors was measured by the
chi-square values, based on the Wald test of the coefficient
associated with each prognostic factor in the Cox model (Marubini
and Valsecchi, 1995). Factors with larger chi-square values were
more significant in each model. The chi-square value in the
ranking of prognostic factors was used because its interpretation is
unrelated to the coding of the covariate. The interpretation of the
hazard ratio depends on the units or coding of the covariate.
The predictor with the highest level of statistical significance was
used to introduce the model; other variables were then evaluated
for further predictive information and added in turn, beginning
with the variables with the highest level of statistical significance
(i.e. the lowest P-values) and continuing until the P-value for the
variable added exceeded 0.05. Continuous prognostic variables
were also considered for inclusion in the model as dichotomous
variables using various cutoff points only if they attained a P-value
of p0.1 in the univariate analysis. On the other hand, discrete
variables with more than two categories were analysed by means of
categories or indicator variables. Cases with unknown factors were
excluded in the initial Cox regression analysis. If a factor did not
predict for the event of interest, the cases with unknown values for
that factor were again added, and the Cox regression was repeated
with that particular factor dropped. Interactions between variables
were not explored. In the derived model, plotting the log-minus-
log survival function tested the proportionality assumption
(Kalbfleisch and Prentice, 1980), and the goodness of fit was
judged by plotting the cumulative baseline hazard function for
residuals (Kay, 1977). We also compared the survival functions for
variables after stratifying for baseline differences in additional
variables (Kalbfleisch and Prentice, 1980). All reported P-values
were two-tailed. We performed all data analyses using SAS System
for Windows, release 8.02 and SPSS release 10.0.1 for Windows.
RESULTS
According to inclusion criteria, 126 patients were accrued and all
were evaluable for response and toxicity analysis. Diagnosis was
made by core biopsy or FNA in 89 (71%) and 37 (29%) of patients,
respectively. Their median age was 41 years (95% CI, 40.1–43.7).
Patient and disease characteristics are depicted in Table 1. Most
patients were premenopausal (79%) and approximately more than
two-thirds (67%) had stage IIIA or IIIB.
Neoadjuvant treatment
The median number of cycles of neoadjuvant chemotherapy was 3
(range, 5). Five patients received two additional cycles of
doxorubicin and cyclophosphamide (AC) preoperatively after
inadequate response to TP.
Clinical response
The mean primary baseline tumour size was 7cm (95% CI, 7.3–
8.5), while the mean size following chemotherapy was 2.2cm (95%
CI, 2.5–3.8). This difference was highly significant (Po0.0001).
Clinical assessment of the primary tumour and the axillary nodal
status after primary chemotherapy showed that 35 patients (28%)
achieved cCR, while 80 (63%) demonstrated cPR to the primary
chemotherapy. The remaining 11 patients (9%) had cSD (nine
patients) and cPD (two patients). Of the five patients who achieved
inadequate response to initial TP, four demonstrated cPR after the
addition of AC.
Surgery
Modified radical mastectomy was performed in 86 patients (68%),
while 36 (29%) had breast-conserving surgery. One patient had
simple mastectomy and, in three patients, surgery was not
performed due to disease progression and/or patient refusal.
Axillary nodal dissection was performed in all except four patients.
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resection margins were close or focally involved in 14 patients.
Pathological response
Pathological status of the primary tumour was known in 123
patients, while the axillary nodal status was pathologically known
in 122 patients. The median number of dissected and positive
axillary lymph nodes was 14 (range, 40) and 1 (range, 19),
respectively. Table 2 shows that of the 123 patients, 29 patients
(24%) had no invasive tumour (eight had noninvasive intraductal
carcinoma in situ). Additionally, in nine patients (7%) only a
microinvasive cancer was found and of these, five had negative
axillary nodes. The table also shows that among those who had
undergone surgery and had their axillary status known, the
complete pathological response, where there were no invasive
primary tumour and no axillary involvement, was 16% (20 of 122
patients). Additionally, five patients had negative axillary nodes
and only a microinvasive cancer. The table also shows that patients
with a pCR of the primary tumour were more likely to have a
negative axillary lymph node status (20 of 29; 69% vs 22 of 93; 24%,
Po0.0001).
Of the 37 patients who were initially diagnosed with FNA only,
only two had no invasive primary tumour and no axillary
involvement; however, during primary chemotherapy one demon-
strated cCR and another cPR. The remaining patients were found
to have either residual invasive disease (nine patients), axillary
lymph node involvement (13 patients), or residual invasive tumour
and axillary disease (13 patients).
Analysis of the clinical and pathological response according to
the tumour receptor status was also carried out. Of the 96 patients
with known ER, cCR was achieved in 10/51 (20%) ER  patients vs
17/45 (38%) in ERþ patients (P¼0.048). Similarly, pCR was
attained in 1/51 (2%) and in 13/45 (29%), respectively (Po0.0001).
On the other hand, while PR status was not related to cCR, it was
significantly associated with pCR (1/46 (2%) in PR  patients vs 13/
50 (26%) in PRþ patients, P¼0.0003). On the other hand, the
stepwise multivariate logistic regression showed that failing to
attain cCR was the only independent factor that predicted no pCR
(odds ratio¼3.02; 95% CI 1.65–5.52; P-value o0.0001).
Agreement between cCR and pCR of the primary tumour was
evaluated. It was shown that concordance was demonstrated in 90
of the 123 patients (73%) with known pathologic data of the
primary tumour. The k-test was 0.313, which only suggests a
moderate agreement between clinical and pathologic (Brookmeyer
and Crowley, 1982).
Adjuvant therapy
Following surgery, adjuvant chemotherapy was offered to 117
patients. In all, 60 patients received FAC, 50 received AC, and
seven received TP. The median number of cycles given was 4.
Following adjuvant chemotherapy, radiotherapy was derived to
120 patients (95%) and adjuvant tamoxifen intended for 5 years
was offered to 65 patients (52%) following radiotherapy.
Overall survival
At a median follow-up of 37.5 months (95% CI, 31.5–43.3), 90
patients (71%) were alive and disease-free, 20 (16%) were alive
with disease, and the remaining 16 (13%) were dead. The median
OS was not reached; however, the projected 5-year OS (þSD) was
85þ4% (Figure 1).
Relapse and DFS
Of all 123 patients who had surgery, 35 (29%) experienced relapse.
Distant relapse only or locoregional relapse only was demonstrated
Table 2 Pathological data of the 123 patients who underwent surgery
No. of patients: pathological nodal status
Pathology of the
primary tumour N0 N1–3 N4–9 XN10 Unknown
T0 20 8 1
T1A 5 4
T 1 B 3422
T 1 C 6743
T2 6 12 15 9
T 3 2252 1
Total 42 37 27 16 1
Table 1 Patient and disease characteristics
Variables No. (%)
Year of diagnosis
1995–1997 43 (34)
1998–2000 83 (76)
Menopausal status
Premenopausal 100 (79)
Postmenopausal 26 (21)
Age (years)
o50 103 (82)
X50 23 (18)
Primary tumour
T2 15 (12)
T3 64 (51)
T4 47 (37)
Clinical nodal status
N0 40 (32)
N1 65 (52)
N2–N3 21 (17)
Clinical nodal size
Negative 40 (32)
o2.5cm 60 (48)
More than 2.5cm 26 (20)
Stage
IIA 2 (2)
IIB 40 (32)
IIIA 35 (28)
IIIB 49 (39)
Grade
G1 4 (3)
G2 55 (44)
G3 51 (40)
Unknown 16 (13)
Vascular invasion
Negative 83 (66)
Positive 24 (19)
Unknown 19 (15)
Oestrogen receptor
Positive 53 (42)
Negative 43 (34)
Unknown 30 (24)
Progesterone receptor
Positive 47 (37)
Negative 49 (39)
Unknown 30 (24)
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lin 19 (15%), and six (5%) patients, respectively. Ten patients (8%)
had distant relapse concurrently with local or regional relapse.
Two events of contralateral breast recurrence were experienced,
one in association with local and distant relapse and the other as a
lone event. Of patients with close or focally involved margins (15
patients), six did not demonstrate relapse, while four, three, and
two showed local or locoregional relapse, locoregional and distant
relapse, and distant relapse only, respectively. The median DFS
was not reached; nevertheless, the projected 5-year DFS (þSD)
was 63þ5% (Figure 2).
Univariate and multivariate analyses of prognostic factors
of OS and DFS
Table 3 shows the univariate analysis of prognostic factors of OS
and DFS. For OS, the following variables were statistically
significant: clinical primary tumour stage, nodal status at baseline,
clinical baseline stage, postneoadjuvant chemotherapy clinical
primary tumour stage, pathological primary tumour, pathological
nodal status, pathological stage, and adjuvant radiotherapy. On the
other hand, the variables that were significant prognostically for
DFS were: clinical primary tumour stage, clinical baseline stage,
postneoadjuvant chemotherapy clinical primary tumour stage,
pathological primary tumour, pathological nodal status, patholo-
gical stage, and adjuvant radiotherapy.
Table 3 Univariate analyses of the effect of variables on overall survival
(OS) and disease-free survival (DFS)
OS DFS
Variable No. (% survival) P-value % DFS P-value
Age (years) 0.36 0.22
o50 103 (88) 73
450 23 (83) 55
Menopausal status 0.52 0.004
Premenopausal 100 (88)
Postmenopausal 26 (85)
Clinical primary tumour (baseline) 0.01 0.14
T2 15 (93) 80
T3 64 (94) 80
T4 47 (77) 57
Clinical nodal status (baseline) 0.01 0.02
N0 40 (90) 78
N1 65 (92) 72
N2+N3 21 (67) 57
Clinical stage (baseline) 0.023 0.41
II 42 (92) 79
IIIA 35 (94) 80
IIIB 49 (78) 59
Tumour grade (known in 110
patients)
0.43 0.20
G1+G2 59 (88) 73
G3 51 (82) 63
Oestrogen receptor 0.35 0.84
Positive 53 (87) 64
Negative 43 (93) 81
Unknown 30 (80) 70
Progesterone receptor 0.53 0.07
Positive 47 (89) 74
Negative 49 (90) 69
Unknown 30 (80) 70
Diagnosis to primary
chemotherapy (days)
0.57 0.04
o21 94 (86) 76
421 32 (90) 59
Clinical primary tumour
(postneoadjuvant chemotherapy)
0.004 0.64
T0 37 (84) 70
T1 25 (100) 80
T2 40 (93) 77
T3+T4 24 (71) 54
Clinical nodal status
(postadjuvant chemotherapy)
0.28 0.41
N0 97 (89) 72
N1+N2 29 (83) 69
Clinical response 0..72
cCR 35 (89) 77
ocCR 91 (87) 69
Tumour pathologic response
(123 patients)
0.026 0.0002
T0 29 (97) 93
T1 40 (93) 80
T2 43 (84) 56
T3 11 (73) 55
Primary tumour pathologic
response (123 patients)
0.09 0.002
pCR 29 (97) 93
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Figure 1 Overall survival.
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Figure 2 Disease-free survival.
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model failed to identify independent prognostic factors for OS. On
the other hand, clinical response of the primary tumour (T0 vs
4T0; odd ratio¼0.60 (95% CI 0.39–0.94)), pathological response
of the primary tumour (T0 vs 4T0; odd ratio¼0.39 (95% CI 0.25–
059)), and the pathological nodal status (negative vs positive; odd
ratio¼0.18 (95% CI 0.05–0.60) were identified as independent
prognostic variables for DFS.
Toxicity
The combination of PC was well tolerated with only rare events of
grade III or IV toxicity. Hypersensitivity reaction to paclitaxel was
reported in three patients and was severe in one with hypotension,
bronchospasm, and seizure. After recovery, paclitaxel was not
resumed. Myelosuppression was minimal; grade III neutropenia
and anaemia developed in 11 and 2% with no grade III
thrombocytopenia. No infection was observed concomitantly to
grade III neutropenia. No treatment-related death occurred during
chemotherapy. Nausea and vomiting were reported in 8%.
Alopecia was universal. Other grade I–II toxicities included
reversible renal impairment, electrolytes disturbance, ototoxicity,
disorders, peripheral neuropathy, and extravasations. Dizziness,
fatigue, and myalgia were commonly reported. Three patients had
their third cycle of chemotherapy delayed by at least 1 week and all
cycles but one were given at full dose.
DISCUSSION
Patients with LABC do very poorly when treated by locoregional
therapy alone, with less than 10–20% of these patients surviving 5
years. Such therapy favourably affects locoregional control, but
most relapses are due to the development of distant metastases
(Zucali et al, 1976; Bruckman et al, 1979). Recently, however,
neoadjuvant chemotherapy regimens have been shown to have a
favourable influence on the outcome of patients with LABC (De
Lena et al, 1981; Hortobagyi et al, 1988; Valagussa et al, 1990;
Anderson et al, 1991; Smith et al, 1993; Scholl et al, 1994; Powles
et al, 1995; Smith et al, 1995; Bonadonna et al, 1998; Fisher et al,
1998; Kuerer et al, 1999; Von Minckwitz et al, 1999; Wolmark et al,
2001).
Complete and partial clinical response to PC was demonstrated
in 28 and 63% of patients, respectively. Moreover, the primary
tumour showed no invasive component in 24% of patients and
only microinvasive disease in an additional 7%; besides, among
patients who had surgery and axillary dissection, 16% patients had
no microscopic evidence of invasive cancer in their breast and
axillary specimens. In the latter group, only one patient subse-
quently developed recurrence. While it may be possible that the
two patients who had no pathological evidence of disease post
neoadjuvant chemotherapy and were originally diagnosed using
FNA only might have had in situ disease, it is rather unlikely
considering the demonstrated clinical response during induction
therapy.
The 16% rate of complete eradication of invasive disease is
comparable to the 12% rate achieved using four cycles of FAC
preoperatively in 372 patients in the MD Anderson study (Kuerer
et al, 1999). Moreover, similar to the findings in the latter series,
our data also showed that a pathologic complete primary tumour
response was predictive of a complete axillary lymph node
response (Po0.0001).
Considering that adverse prognostic features prevailed in
patients in the current series, which includes a median tumour
size of 7cm, the current data provide further support to our earlier
conclusion about the efficacy of primary PC for patients with
LABC (Ezzat et al, 2000). At a median follow-up of 37 months, 71%
were alive and disease-free, 16% were alive with disease, and the
remaining 13% were dead. The projected 5-year OS and DFS was
85 and 63%, respectively. These survival data are comparable to
those results reported in other series that included patients with
more favourable prognostic characteristics (Bonadonna et al, 1998;
Fisher et al, 1998; Kuerer et al, 1999; Wolmark et al, 2001). As a
large number of patients received adjuvant chemotherapy (92%),
radiation therapy (95%), and tamoxifen (52%), the independent
additional contributions of these modalities to the obtained
favourable results could not be ascertained.
While ER- or PR-disease was shown to be associated with higher
clinical and/or pathological response, failure to attain cCR was the
only variable identified that predicts failure to achieve pCR.
Nonetheless, the overall agreement between cCR and pCR was only
moderate. In contrast, in a recently published series from MD
Anderson, negative ER status and higher nuclear grade were
independently associated with pCR (Kuerer et al, 1999).
While no variable could be identified to prognosticate OS
independently, clinical response of the primary tumour,
pathological response of the primary tumour, and the pathological
nodal status were identified as independent prognostic variables
for DFS. In the NSABB B-18 study, the 9-year follow-up
demonstrated significant associations between clinical response
and achieving pCR and OS, DFS, and relapse-free survival
(Wolmark et al, 2001). Also shown were the associations
between pathologic lymph node status and survival. In the latter
study, these significant associations persisted after adjustment for
clinical tumour size at randomisation, clinical lymph node status,
and age.
In conclusion, neoadjuvant PC as used in this phase II study in a
multidisciplinary strategy was highly effective with an acceptable
safety profile. Clinical and pathologic responses remain the most
important variables that predict outcome.
opCR 94 (86) 66
Pathological nodal status (122
patients)
0.08 0.0001
Negative 42 (95) 93
Positive 80 (86) 62
Pathological nodal status (122
patients)
0.047 o0.0001
Negative 42 (95) 93
1–3 positive nodes 37 (92) 73
4–9 positive nodes 27 (85) 59
More than 9 positive nodes 16 (75) 44
Pathologic stage
(postneoadjuvant chemotherapy)
0.017 0.0006
T0N0 20 (95) 95
I 13 (100) 100
II (A+B) 81 (86) 64
III (A+B) 12 (67) 50
Adjuvant radiotherapy 0.029 0.01
Yes 120 (88) 73
None 6 (67) 33
Adjuvant tamoxifen (receptor-
positive patients only, 57)
0.46 0.51
Yes (46 patients) 42 (91) 70
No (11 patients) 9 (82) 63
Table 3 (continued)
OS DFS
Variable No. (% survival) P-value % DFS P-value
Paclitaxel–cisplatin for locally advanced breast cancer
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